Dual fluorescence imaging-guided programmed delivery of doxorubicin and CpG nanoparticles to modulate tumor microenvironment for effective chemo-immunotherapy

Dong, Xia; Yang, Afeng; Bai, Yun; Kong, Deling; Lv, Feng

doi:10.1016/j.biomaterials.2019.119659

Cited by 85 publications

(62 citation statements)

References 51 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Recently, the combination of CpG oligodeoxynucleotides (CpG; TLR9 agonist) with Ferumoxytol ® (FMT; an FDA approved drug for the treatment of iron deficiency) showed a synergistic antitumoral effect, mediated by an increased infiltration of M1-like macrophages (expressing F4/80 and iNOS) in a murine model of NSCLC [ 128 ]. A new hydrogel loaded with CpG and Doxorubicin showed also antitumoral efficacy, mediated by a decrease in M2-like TAMs and MDSCs, upon intratumoral implantation in a murine melanoma model [ 129 ]. Regarding the activation of extracellular TLRs, Diprovocim, a small drug agonist of TLR2, identified through a screening of molecules on macrophages, showed efficacy in combination with anti-PD-L1 antibodies in a melanoma model [ 130 ].…”

Section: Tlr or Sting Signaling Activation To Reprogram Tamsmentioning

confidence: 99%

Targeting Tumor-Associated Macrophages in Anti-Cancer Therapies: Convincing the Traitors to Do the Right Thing

Belgiovine

Digifico

Anfray

et al. 2020

JCM

View full text Add to dashboard Cite

In the last decade, it has been well-established that tumor-infiltrating myeloid cells fuel not only the process of carcinogenesis through cancer-related inflammation mechanisms, but also tumor progression, invasion, and metastasis. In particular, tumor-associated macrophages (TAMs) are the most abundant leucocyte subset in many cancers and play a major role in the creation of a protective niche for tumor cells. Their ability to generate an immune-suppressive environment is crucial to escape the immune system and to allow the tumor to proliferate and metastasize to distant sites. Conventional therapies, including chemotherapy and radiotherapy, are often not able to limit cancer growth due to the presence of pro-tumoral TAMs; these are also responsible for the failure of novel immunotherapies based on immune-checkpoint inhibition. Several novel therapeutic strategies have been implemented to deplete TAMs; however, more recent approaches aim to use TAMs themselves as weapons to fight cancer. Exploiting their functional plasticity, the reprogramming of TAMs aims to convert immunosuppressive and pro-tumoral macrophages into immunostimulatory and anti-tumor cytotoxic effector cells. This shift eventually leads to the reconstitution of a reactive immune landscape able to destroy the tumor. In this review, we summarize the current knowledge on strategies able to reprogram TAMs with single as well as combination therapies.

show abstract

Section: Tlr or Sting Signaling Activation To Reprogram Tamsmentioning

confidence: 99%

Targeting Tumor-Associated Macrophages in Anti-Cancer Therapies: Convincing the Traitors to Do the Right Thing

Belgiovine

Digifico

Anfray

et al. 2020

JCM

View full text Add to dashboard Cite

show abstract

“…Nanogels, with nano-sized hydrogel scaffold, good biocompatibility, high water contents and great compatibility with various therapeutic agents (such as small-molecule drugs and bio-macromolecules) have been considered as promising NDDS for effective chemoimmunotherapy. Multifunctional nanogels could be rationally designed for chemoimmunotherapy, by decorating with targeting ligands, synthesizing responsive functional bonds and so on [114,115,[148][149][150]. For example, Chen et al have reported a thermo-sensitive hydrogel co-loaded DOX/IL-2/IFN-γ, which showed improved therapeutic efficacy B16F10 melanoma tumor by enhancing tumor cell apoptosis and increasing proliferation of the CD3 + /CD4 + T cells and CD3 + / CD8 + T cells [151].…”

Section: Nanogelsmentioning

confidence: 99%

Section: Nanocarriers For Cancer Chemoimmunotherapymentioning

confidence: 99%

A Review on Nano-Based Drug Delivery System for Cancer Chemoimmunotherapy

et al. 2020

View full text Add to dashboard Cite

Although notable progress has been made on novel cancer treatments, the overall survival rate and therapeutic effects are still unsatisfactory for cancer patients. Chemoimmunotherapy, combining chemotherapeutics and immunotherapeutic drugs, has emerged as a promising approach for cancer treatment, with the advantages of cooperating two kinds of treatment mechanism, reducing the dosage of the drug and enhancing therapeutic effect. Moreover, nano-based drug delivery system (NDDS) was applied to encapsulate chemotherapeutic agents and exhibited outstanding properties such as targeted delivery, tumor microenvironment response and site-specific release. Several nanocarriers have been approved in clinical cancer chemotherapy and showed significant improvement in therapeutic efficiency compared with traditional formulations, such as liposomes (Doxil®, Lipusu®), nanoparticles (Abraxane®) and micelles (Genexol-PM®). The applications of NDDS to chemoimmunotherapy would be a powerful strategy for future cancer treatment, which could greatly enhance the therapeutic efficacy, reduce the side effects and optimize the clinical outcomes of cancer patients. Herein, the current approaches of cancer immunotherapy and chemoimmunotherapy were discussed, and recent advances of NDDS applied for chemoimmunotherapy were further reviewed.

show abstract

“…High-resolution imaging by multifunctional nanoprobes can also elucidate the mechanisms of immunotherapy 53 , 54 via real-time monitoring of immune cells in the TME and the biodistribution of immunomodulatory drugs at the target site 21 , 32 . Rinat et al 55 labeled melanoma-specific T-cell receptor (TCR)-expressing T cells with Au nanoparticles (AuNNPs) for CT image-guided therapy.…”

Section: Image-guided Immunotherapymentioning

confidence: 99%

Tumor immunotherapy and multi-mode therapies mediated by medical imaging of nanoprobes

Yang¹,

Guan²,

Zhang³

2021

Theranostics

View full text Add to dashboard Cite

Immunotherapy is an effective tumor treatment strategy that has several advantages over conventional methods such as surgery, radiotherapy and chemotherapy. Studies show that multifunctional nanoprobes can achieve multi-mode image-guided multiple tumor treatment modes. The tumor cells killed by chemotherapies or phototherapies release antigens that trigger an immune response and augment the effects of tumor immunotherapy. Thus, combining immunotherapy and multifunctional nanoprobes can achieve early cancer diagnosis and treatment. In this review, we have summarized the current research on the applications of multifunctional nanoprobes in image-guided immunotherapy. In addition, image-guided synergistic chemotherapy/photothermal therapy/photodynamic therapy and immunotherapy have also been discussed. Furthermore, the application potential and clinical prospects of multifunctional nanoprobes in combination with immunotherapy have been assessed.

show abstract

Dual fluorescence imaging-guided programmed delivery of doxorubicin and CpG nanoparticles to modulate tumor microenvironment for effective chemo-immunotherapy

Cited by 85 publications

References 51 publications

Targeting Tumor-Associated Macrophages in Anti-Cancer Therapies: Convincing the Traitors to Do the Right Thing

Targeting Tumor-Associated Macrophages in Anti-Cancer Therapies: Convincing the Traitors to Do the Right Thing

A Review on Nano-Based Drug Delivery System for Cancer Chemoimmunotherapy

Tumor immunotherapy and multi-mode therapies mediated by medical imaging of nanoprobes

Contact Info

Product

Resources

About